Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.

Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R.

Br J Haematol. 2017 Oct;179(2):298-307. doi: 10.1111/bjh.14844. Epub 2017 Jul 12.

PMID:
28699675
2.

Outcome measures for adult and pediatric hemophilia patients with inhibitors.

Hermans C, Auerswald G, Benson G, Dolan G, Duffy A, Jiménez-Yuste V, Ljung R, Morfini M, Lambert T, Osooli M, Zupančić Šalek S.

Eur J Haematol. 2017 Aug;99(2):103-111. doi: 10.1111/ejh.12881. Epub 2017 Apr 25. Review.

PMID:
28332238
3.

Pain and pain management in haemophilia.

Auerswald G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Lambert T, Šalek SZ.

Blood Coagul Fibrinolysis. 2016 Dec;27(8):845-854.

4.

The burden of inhibitors in haemophilia patients.

Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S.

Thromb Haemost. 2016 Aug 31;116 Suppl 1:S10-7. doi: 10.1160/TH16-01-0049. Epub 2016 Aug 16.

PMID:
27528280
5.

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.

Napolitano M, Di Minno MN, Batorova A, Dolce A, Giansily-Blaizot M, Ingerslev J, Schved JF, Auerswald G, Kenet G, Karimi M, Shamsi T, Ruiz de Sáez A, Dolatkhah R, Chuansumrit A, Bertrand MA, Mariani G.

Haemophilia. 2016 Sep;22(5):752-9. doi: 10.1111/hae.12978. Epub 2016 Jun 24.

PMID:
27338009
6.

Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.

Escobar MA, Auerswald G, Austin S, Huang JN, Norton M, Millar CM.

Haemophilia. 2016 Sep;22(5):713-20. doi: 10.1111/hae.12954. Epub 2016 May 24.

PMID:
27217097
7.

Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.

Austin SK, Kavakli K, Norton M, Peyvandi F, Shapiro A; FX Investigators Group.

Haemophilia. 2016 May;22(3):419-25. doi: 10.1111/hae.12893. Epub 2016 Mar 8.

PMID:
27197801
8.

Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.

Austin SK, Brindley C, Kavakli K, Norton M, Shapiro A; FX Investigators Group.

Haemophilia. 2016 May;22(3):426-32. doi: 10.1111/hae.12894. Epub 2016 Feb 15.

PMID:
26879266
9.

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, von Depka Prondzinski M, Altisent C, Castaman G, Yamamoto K, Álvarez-Roman MT, Voigt C, Blackman N, Jacobs I; PROLONG-9FP Investigators Study Group.

Blood. 2016 Apr 7;127(14):1761-9. doi: 10.1182/blood-2015-09-669234. Epub 2016 Jan 11.

10.

Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.

Šalek SZ, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Santagostino E, Lambert T.

Blood Transfus. 2015 Dec 1;15(1):77-84. doi: 10.2450/2015.0127-15. [Epub ahead of print]

11.

Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors.

van den Berg HM, Hashemi SM, Fischer K, Petrini P, Ljung R, Rafowicz A, Carcao M, Auerswald G, Kurnik K, Kenet G, Santagostino E; PedNet Study group.

Thromb Haemost. 2016 Apr;115(4):729-37. doi: 10.1160/TH15-08-0692. Epub 2015 Dec 3.

PMID:
26632988
12.

Inhibitor development in non-severe haemophilia across Europe.

Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M; EUHASS Participants.

Thromb Haemost. 2015 Oct;114(4):670-5. doi: 10.1160/TH14-12-1044. Epub 2015 Aug 13. Erratum in: Thromb Haemost. 2016 Mar;115(3):684. Hollingsworth, R [Added].

PMID:
26293381
13.

FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies.

Fischer K, Iorio A, Hollingsworth R, Makris M; EUHASS collaborators.

Haemophilia. 2016 Jan;22(1):e36-8. doi: 10.1111/hae.12764. Epub 2015 Jul 24. No abstract available.

PMID:
26208036
14.

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.

Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O; ObsITI study group; ObsITI committee.

Haemophilia. 2016 Jan;22(1):87-95. doi: 10.1111/hae.12774. Epub 2015 Jul 23.

PMID:
26202305
15.

The EPIC study: a lesson to learn.

Auerswald G, Kurnik K, Aledort LM, Chehadeh H, Loew-Baselli A, Steinitz K, Reininger AJ; EPIC clinical study group.

Haemophilia. 2015 Sep;21(5):622-8. doi: 10.1111/hae.12666. Epub 2015 Apr 23.

PMID:
25912619
16.

Rationale for individualizing haemophilia care.

Sørensen B, Auerswald G, Benson G, Elezović I, Felder M, Lambert T, Morfini M, Remor E, Salaj P, Santagostino E, Šalek SZ, Ljung R.

Blood Coagul Fibrinolysis. 2015 Dec;26(8):849-57. doi: 10.1097/MBC.0000000000000225. Review.

PMID:
25396764
17.

Switching treatments in haemophilia: is there a risk of inhibitor development?

Santagostino E, Auerswald G, Benson G, Dolan G, Jiménez-Yuste V, Lambert T, Ljung R, Morfini M, Remor E, Zupančić Šalek S.

Eur J Haematol. 2015 Apr;94(4):284-9. doi: 10.1111/ejh.12433. Epub 2014 Sep 17. Review.

18.

Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future.

Jiménez-Yuste V, Auerswald G, Benson G, Lambert T, Morfini M, Remor E, Salek SZ.

Blood Transfus. 2014 Jul;12(3):314-9. doi: 10.2450/2014.0298-13. Review. No abstract available.

19.

Similar bleeding phenotype in young children with haemophilia A or B: a cohort study.

Clausen N, Petrini P, Claeyssens-Donadel S, Gouw SC, Liesner R; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group.

Haemophilia. 2014 Nov;20(6):747-55. doi: 10.1111/hae.12470. Epub 2014 Jun 3.

PMID:
24893572
20.

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.

Morfini M, Batorova A, Mariani G, Auerswald G, Bernardi F, Di Minno G, Dolce A, Fede C, Giansily-Blaizot M, Ingerslev J, Martinowitz U, Napolitano M, Pinotti M, Schved JF; International FVII [IF7] and Seven Treatment Evaluation Registry [STER] Study Groups.

Thromb Haemost. 2014 Aug;112(2):424-5. doi: 10.1160/TH13-12-1045. Epub 2014 Apr 24. No abstract available.

PMID:
24763923

Supplemental Content

Loading ...
Support Center